Prothena Co. PLC (NASDAQ:PRTA) Forecasted to Earn Q3 2019 Earnings of ($0.54) Per Share

Prothena Co. PLC (NASDAQ:PRTA) – Equities researchers at Jefferies Financial Group lifted their Q3 2019 earnings per share estimates for shares of Prothena in a research note issued to investors on Tuesday, August 6th, according to Zacks Investment Research. Jefferies Financial Group analyst M. Yee now anticipates that the biotechnology company will post earnings per share of ($0.54) for the quarter, up from their previous estimate of ($0.58). Jefferies Financial Group also issued estimates for Prothena’s Q4 2019 earnings at ($0.60) EPS, FY2019 earnings at ($2.07) EPS, FY2020 earnings at ($1.53) EPS and FY2021 earnings at ($3.79) EPS.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.16. The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.22 million. Prothena had a negative return on equity of 27.59% and a negative net margin of 10,435.79%.

A number of other research firms also recently weighed in on PRTA. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research report on Thursday, May 16th. ValuEngine upgraded Prothena from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub downgraded Prothena from a “sell” rating to a “strong sell” rating in a research report on Thursday. Zacks Investment Research upgraded Prothena from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Wednesday, June 19th. Finally, Barclays restated a “sell” rating and issued a $9.00 target price on shares of Prothena in a research report on Friday, May 31st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $11.26.

Shares of NASDAQ PRTA opened at $7.60 on Friday. The company has a current ratio of 14.94, a quick ratio of 14.95 and a debt-to-equity ratio of 0.07. Prothena has a 12-month low of $7.52 and a 12-month high of $15.91. The stock has a 50 day simple moving average of $9.61 and a 200-day simple moving average of $10.92.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRTA. Bank of Montreal Can acquired a new stake in shares of Prothena during the 2nd quarter valued at $36,000. Meeder Asset Management Inc. acquired a new stake in shares of Prothena during the 2nd quarter valued at $37,000. Quantamental Technologies LLC lifted its position in shares of Prothena by 142.9% during the 1st quarter. Quantamental Technologies LLC now owns 4,129 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,429 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of Prothena during the 2nd quarter valued at $109,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Prothena during the 1st quarter valued at $114,000. Hedge funds and other institutional investors own 98.89% of the company’s stock.

About Prothena

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Featured Article: How a Put Option Works

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.